MarketScreener Homepage > Equities > Euronext Growth Paris > Carmat ALCAR FR0010907956

Report

Real-time Euronext Growth Paris - 01/28 08:13:56 am
26.8	EUR		-5.47%

10:48a

CARMAT : Back towards the lower end of the range

01/18

CARMAT : 2021 Financial Calendar

01/06

EUROPE : European stocks jump on vaccine hopes, Democrats on cusp of Senate victory

Summary

Quotes 5-day view Real-time Quote.

Real-time Euronext Growth Paris

01/22/2021	01/25/2021	01/26/2021	01/27/2021	01/28/2021	Date
29.85(c)	28.8(c)	28.8(c)	28.35(c)	26.8	Last
62 613	45 568	47 854	23 775	72 930	Volume
-3.86%	-3.52%	0.00%	-1.56%	-5.47%	Change

More quotes

Financials

Sales 2020	0,32 M 0,39 M 0,39 M
Net income 2020	-41,8 M -50,6 M -50,6 M
Net Debt 2020	16,9 M 20,5 M 20,5 M
P/E ratio 2020	-8,32x
Yield 2020	-

Sales 2021	10,3 M 12,5 M 12,5 M
Net income 2021	-39,1 M -47,3 M -47,3 M
Net Debt 2021	57,2 M 69,2 M 69,2 M
P/E ratio 2021	-8,41x
Yield 2021	-

Capitalization	359 M 434 M 435 M
EV / Sales 2020	1 158x
EV / Sales 2021	40,4x
Nbr of Employees	108
Free-Float	41,4%

More Financials

Company

Carmat specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.

Sector

Medical Equipment, Supplies & Distribution

Calendar

02/10

Earnings Release

More about the company

Notations Surperformance© of Carmat

Trading Rating :

Investor Rating :

More Ratings

All news about CARMAT

01/18	CARMAT : 2021 Financial Calendar	BU
01/06	EUROPE : European stocks jump on vaccine hopes, Democrats on cusp of Senate vict..	RE
01/06	European stocks jump on vaccine hopes, Democrats on cusp of Senate victory	RE
01/06	CARMAT : Outlines Commercial and Development Plan for Its Total Artificial Heart	BU
2020	CARMAT : Obtains CE Marking For Artificial Heart	MT
2020	CARMAT : Receives the CE Marking for Its Total Artificial Heart	BU
2020	CARMAT : Update on the US Early Feasibility Study	PU
2020	CARMAT : Provides Update on the US Early Feasibility Study	BU
2020	CARMAT : Obtains Non-Dilutive Financing of €10 Million Guaranteed by the French ..	BU
2020	CARMAT : obtains ANSM approval to resume PIVOTAL study implants in France	PU
2020	CARMAT : Obtains ANSM Approval to Resume PIVOTAL Study Implants in France	BU
2020	GLOBAL MARKETS LIVE: Boeing, Airbus, KPN…
2020	CARMAT : is granted €13 million in national innovation funding to conduct the EF..	PU
2020	CARMAT : is granted €13 million in national innovation funding to conduct the EF..	BU
2020	CORRECTING AND REPLACING : CARMAT Reports Its 2020 Half-year Results and Issues ..	BU

More news

News in other languages on CARMAT

01/18	CARMAT : Agenda financier 2021
01/06	Résumé des principales informations économiques du mercredi 6 janvier 2021
01/06	CARMAT : un coeur bientôt à prendre
01/06	EUROPE : Borse Europa In rialzo, bene bancari ed energetici in attesa risultati ..
01/06	EN DIRECT DES MARCHES : Alstom, Rubis, Pixium, Carmat, X-Fab, Amazon, Tiffany, A..

More news

Stock Trading Strategies

	CARMAT - 10:48
Back towards the lower end of the range

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Chart CARMAT

Duration : Period :

Carmat Technical Analysis Chart | ALCAR | FR0010907956 | MarketScreener

Full-screen chart

Technical analysis trends CARMAT

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	5
Average target price	41,81 €
Last Close Price	28,35 €
Spread / Highest target	108%
Spread / Average Target	47,5%
Spread / Lowest Target	6,70%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Stéphane Piat	Chief Executive Officer & Director
Alain Carpentier	Honorary President
Jean-Pierre Garnier	Chairman
Pascale d’Arbonneau	Chief Financial & Administrative Officer
Marc Grimmé	Director-Research & Development

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

CARMAT	0.18%	434



STRYKER CORPORATION	-5.83%	86 714
SMITH & NEPHEW PLC	6.82%	19 348
INSPIRE MEDICAL SYSTEMS, INC.	0.40%	5 086
VENUS MEDTECH (HANGZHOU) INC.	20.24%	4 594
GLAUKOS CORPORATION	17.42%	3 971

More Results